×
QQQ   286.59 (-2.00%)
AAPL   139.09 (-1.81%)
MSFT   259.41 (-2.07%)
META   164.63 (-2.87%)
GOOGL   2,263.89 (-2.28%)
AMZN   108.55 (-4.12%)
TSLA   709.96 (-3.38%)
NVDA   161.30 (-4.38%)
NIO   22.43 (-2.27%)
BABA   117.16 (-1.32%)
AMD   81.19 (-5.77%)
MU   58.73 (-0.09%)
CGC   3.64 (-3.96%)
T   20.78 (+0.05%)
GE   66.06 (-0.97%)
F   12.00 (-0.33%)
DIS   97.88 (+1.31%)
AMC   13.43 (-4.95%)
PFE   50.83 (-2.02%)
PYPL   73.54 (-3.16%)
NFLX   182.14 (-3.70%)
QQQ   286.59 (-2.00%)
AAPL   139.09 (-1.81%)
MSFT   259.41 (-2.07%)
META   164.63 (-2.87%)
GOOGL   2,263.89 (-2.28%)
AMZN   108.55 (-4.12%)
TSLA   709.96 (-3.38%)
NVDA   161.30 (-4.38%)
NIO   22.43 (-2.27%)
BABA   117.16 (-1.32%)
AMD   81.19 (-5.77%)
MU   58.73 (-0.09%)
CGC   3.64 (-3.96%)
T   20.78 (+0.05%)
GE   66.06 (-0.97%)
F   12.00 (-0.33%)
DIS   97.88 (+1.31%)
AMC   13.43 (-4.95%)
PFE   50.83 (-2.02%)
PYPL   73.54 (-3.16%)
NFLX   182.14 (-3.70%)
QQQ   286.59 (-2.00%)
AAPL   139.09 (-1.81%)
MSFT   259.41 (-2.07%)
META   164.63 (-2.87%)
GOOGL   2,263.89 (-2.28%)
AMZN   108.55 (-4.12%)
TSLA   709.96 (-3.38%)
NVDA   161.30 (-4.38%)
NIO   22.43 (-2.27%)
BABA   117.16 (-1.32%)
AMD   81.19 (-5.77%)
MU   58.73 (-0.09%)
CGC   3.64 (-3.96%)
T   20.78 (+0.05%)
GE   66.06 (-0.97%)
F   12.00 (-0.33%)
DIS   97.88 (+1.31%)
AMC   13.43 (-4.95%)
PFE   50.83 (-2.02%)
PYPL   73.54 (-3.16%)
NFLX   182.14 (-3.70%)
QQQ   286.59 (-2.00%)
AAPL   139.09 (-1.81%)
MSFT   259.41 (-2.07%)
META   164.63 (-2.87%)
GOOGL   2,263.89 (-2.28%)
AMZN   108.55 (-4.12%)
TSLA   709.96 (-3.38%)
NVDA   161.30 (-4.38%)
NIO   22.43 (-2.27%)
BABA   117.16 (-1.32%)
AMD   81.19 (-5.77%)
MU   58.73 (-0.09%)
CGC   3.64 (-3.96%)
T   20.78 (+0.05%)
GE   66.06 (-0.97%)
F   12.00 (-0.33%)
DIS   97.88 (+1.31%)
AMC   13.43 (-4.95%)
PFE   50.83 (-2.02%)
PYPL   73.54 (-3.16%)
NFLX   182.14 (-3.70%)
NASDAQ:CGIX

Cancer Genetics Stock Forecast, Price & News

$0.92
+0.08 (+9.51%)
(As of 06/27/2022 12:00 AM ET)
Add
Compare
Today's Range
$0.84
$0.93
50-Day Range
$0.62
$1.12
52-Week Range
$2.11
$17.50
Volume
220,334 shs
Average Volume
2.44 million shs
Market Capitalization
$3.76 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
30 days | 90 days | 365 days | Advanced Chart

Receive CGIX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cancer Genetics and its competitors with MarketBeat's FREE daily newsletter.

CGIX Stock Forecast (MarketRank)

Overall MarketRank

0.00 out of 5 stars

Health Care And Social Assistance Sector

1st out of 1 stocks

Analyst Opinion: 0.0Community Rank: 0.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
Cancer Genetics logo

About Cancer Genetics (NASDAQ:CGIX)

Vyant Bio, Inc. is emerging as an advanced biotechnology drug discovery company. The firm is focused on human-powered scientific and technology-based systems to de-risk and accelerate the discovery and development of therapeutics for biopharma partners, as well as for its proprietary pipeline. The company with capabilities in data, science (both biology and chemistry), engineering, and regulatory, it rapidly identifying small and large molecule therapeutics and derisking decision making through multiple in silico, in vitro, and in vivo modalities. It leveraging these modalities, the company is able to capitalize on repurposed and novel compounds and then partner with others to further develop and commercialize valuable therapeutics and new treatments for patients. It operates two wholly-owned subsidiaries, StemoniX and vivoPharm. Vyant Bio was founded in 1999 and is headquartered in Cherry Hill, NJ.

CGIX Stock News Headlines

See More Headlines

Industry, Sector and Symbol

Industry
N/A
Sub-Industry
N/A
Current Symbol
NASDAQ:CGIX
CIK
N/A
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A

Miscellaneous

Free Float
N/A
Market Cap
$3.76 million
Optionable
Not Optionable
Beta
N/A














Cancer Genetics Frequently Asked Questions

How has Cancer Genetics' stock performed in 2022?

Cancer Genetics' stock was trading at $1.12 at the start of the year. Since then, CGIX shares have decreased by 17.8% and is now trading at $0.9211.
View the best growth stocks for 2022 here
.

Who are Cancer Genetics' key executives?

Cancer Genetics' management team includes the following people:
  • John A. Roberts, President, Chief Executive Officer & Director
  • Andrew D. C. LaFrence, Chief Operating & Financial Officer
  • Robert T. Fremeau, Chief Scientific Officer
  • Ping Yeh, Director & Chief Innovation Officer
  • Ralf Brandt, President-Discovery & Early Development Services

What is Panna Sharma's approval rating as Cancer Genetics' CEO?

28 employees have rated Cancer Genetics CEO Panna Sharma on Glassdoor.com. Panna Sharma has an approval rating of 37% among Cancer Genetics' employees. This puts Panna Sharma in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Cancer Genetics own?

What is Cancer Genetics' stock symbol?

Cancer Genetics trades on the NASDAQ under the ticker symbol "CGIX."

How do I buy shares of Cancer Genetics?

Shares of CGIX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Cancer Genetics' stock price today?

One share of CGIX stock can currently be purchased for approximately $0.92.

How much money does Cancer Genetics make?

Cancer Genetics (NASDAQ:CGIX) has a market capitalization of $3.76 million.

How can I contact Cancer Genetics?

Cancer Genetics' mailing address is 201 State Rt 17 Fl 2, Rutherford, New Jersey 07070-2597. The official website for Cancer Genetics is www.cancergenetics.com. The company can be reached via phone at (201) 479-1357.

This page (NASDAQ:CGIX) was last updated on 6/28/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.